As Boryung has started in-house production of 'Alimta (pemetrexed),' a non-small cell lung cancer (NSCLC) treatment that Boryung acquired the sales right in 2022, attention is drawn to the background.

Analysis indicates that Boryung aims to take a share of the market worth KRW 20 billion as part of a synergistic strategy for operating a manufacturing facility at the Yesan Campus.

According to the pharmaceutical industry on December 25, Boryung withdrew its import approval for two 'Alimta Inj' items that the company had imported from Lily. After that, Boryung is reported to have acquired approval for domestic production of the items.

The current approval and withdrawal are i